vs
Side-by-side financial comparison of Enhabit, Inc. (EHAB) and HUTCHMED (China) Ltd (HCM). Click either name above to swap in a different company.
HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $270.4M, roughly 1.0× Enhabit, Inc.). HUTCHMED (China) Ltd runs the higher net margin — 0.7% vs -14.3%, a 15.0% gap on every dollar of revenue. On growth, Enhabit, Inc. posted the faster year-over-year revenue change (4.7% vs -16.5%). HUTCHMED (China) Ltd produced more free cash flow last quarter ($3.4M vs $3.3M).
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
EHAB vs HCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.4M | $270.8M |
| Net Profit | $-38.7M | $2.0M |
| Gross Margin | — | 37.7% |
| Operating Margin | -12.3% | -13.2% |
| Net Margin | -14.3% | 0.7% |
| Revenue YoY | 4.7% | -16.5% |
| Net Profit YoY | 15.9% | -83.6% |
| EPS (diluted) | $-0.76 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.4M | $270.8M | ||
| Q3 25 | $263.6M | — | ||
| Q2 25 | $266.1M | $277.7M | ||
| Q1 25 | $259.9M | $324.5M | ||
| Q4 24 | $258.2M | — | ||
| Q3 24 | $253.6M | — | ||
| Q2 24 | $260.6M | $305.7M | ||
| Q1 24 | $262.4M | — |
| Q4 25 | $-38.7M | $2.0M | ||
| Q3 25 | $11.1M | — | ||
| Q2 25 | $5.2M | $455.0M | ||
| Q1 25 | $17.8M | $11.9M | ||
| Q4 24 | $-46.0M | — | ||
| Q3 24 | $-110.2M | — | ||
| Q2 24 | $-200.0K | $25.8M | ||
| Q1 24 | $200.0K | — |
| Q4 25 | — | 37.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 48.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 41.1% | ||
| Q1 24 | — | — |
| Q4 25 | -12.3% | -13.2% | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 6.3% | -1.3% | ||
| Q1 25 | 6.1% | -5.0% | ||
| Q4 24 | -16.0% | — | ||
| Q3 24 | -38.6% | — | ||
| Q2 24 | 4.3% | -9.0% | ||
| Q1 24 | 4.9% | — |
| Q4 25 | -14.3% | 0.7% | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 2.0% | 163.8% | ||
| Q1 25 | 6.8% | 3.7% | ||
| Q4 24 | -17.8% | — | ||
| Q3 24 | -43.5% | — | ||
| Q2 24 | -0.1% | 8.4% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | $-0.76 | $0.00 | ||
| Q3 25 | $0.22 | — | ||
| Q2 25 | $0.10 | $0.52 | ||
| Q1 25 | $0.35 | $0.01 | ||
| Q4 24 | $-0.92 | — | ||
| Q3 24 | $-2.20 | — | ||
| Q2 24 | $0.00 | $0.03 | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.6M | $1.4B |
| Total DebtLower is stronger | $426.0M | $93.2M |
| Stockholders' EquityBook value | $534.0M | $1.2B |
| Total Assets | $1.2B | $1.8B |
| Debt / EquityLower = less leverage | 0.80× | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.6M | $1.4B | ||
| Q3 25 | $56.9M | — | ||
| Q2 25 | $37.1M | $1.4B | ||
| Q1 25 | $39.5M | $836.1M | ||
| Q4 24 | $28.4M | — | ||
| Q3 24 | $45.7M | — | ||
| Q2 24 | $28.5M | $802.5M | ||
| Q1 24 | $36.5M | — |
| Q4 25 | $426.0M | $93.2M | ||
| Q3 25 | $441.5M | — | ||
| Q2 25 | $456.9M | $93.4M | ||
| Q1 25 | $467.3M | $82.8M | ||
| Q4 24 | $492.6M | — | ||
| Q3 24 | $502.9M | — | ||
| Q2 24 | $512.7M | $82.1M | ||
| Q1 24 | $526.7M | — |
| Q4 25 | $534.0M | $1.2B | ||
| Q3 25 | $566.8M | — | ||
| Q2 25 | $552.4M | $1.2B | ||
| Q1 25 | $543.2M | $759.9M | ||
| Q4 24 | $523.5M | — | ||
| Q3 24 | $566.1M | — | ||
| Q2 24 | $674.3M | $740.1M | ||
| Q1 24 | $672.3M | — |
| Q4 25 | $1.2B | $1.8B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.4B | $1.3B | ||
| Q1 24 | $1.4B | — |
| Q4 25 | 0.80× | 0.08× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.83× | 0.08× | ||
| Q1 25 | 0.86× | 0.11× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.76× | 0.11× | ||
| Q1 24 | 0.78× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | $8.2M |
| Free Cash FlowOCF − Capex | $3.3M | $3.4M |
| FCF MarginFCF / Revenue | 1.2% | 1.2% |
| Capex IntensityCapex / Revenue | 0.4% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 4.21× |
| TTM Free Cash FlowTrailing 4 quarters | $65.8M | $-96.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.4M | $8.2M | ||
| Q3 25 | $37.8M | — | ||
| Q2 25 | $10.6M | $-72.9M | ||
| Q1 25 | $17.9M | $40.3M | ||
| Q4 24 | $-4.1M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $9.6M | $-39.8M | ||
| Q1 24 | $17.3M | — |
| Q4 25 | $3.3M | $3.4M | ||
| Q3 25 | $36.2M | — | ||
| Q2 25 | $8.7M | $-82.2M | ||
| Q1 25 | $17.6M | $32.5M | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $27.7M | — | ||
| Q2 24 | $8.9M | $-49.9M | ||
| Q1 24 | $15.5M | — |
| Q4 25 | 1.2% | 1.2% | ||
| Q3 25 | 13.7% | — | ||
| Q2 25 | 3.3% | -29.6% | ||
| Q1 25 | 6.8% | 10.0% | ||
| Q4 24 | -1.8% | — | ||
| Q3 24 | 10.9% | — | ||
| Q2 24 | 3.4% | -16.3% | ||
| Q1 24 | 5.9% | — |
| Q4 25 | 0.4% | 1.8% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 0.7% | 3.3% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.3% | 3.3% | ||
| Q1 24 | 0.7% | — |
| Q4 25 | — | 4.21× | ||
| Q3 25 | 3.41× | — | ||
| Q2 25 | 2.04× | -0.16× | ||
| Q1 25 | 1.01× | 3.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.54× | ||
| Q1 24 | 86.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
HCM
Segment breakdown not available.
